Transition from Enoxaparin to Unfractionated Heparin in End‑Stage Renal Disease

Pharmacokinetic Considerations in ESRD

In patients with creatinine clearance < 30 mL/min, enoxaparin clearance is reduced by approximately 44 %, producing drug accumulation and a markedly prolonged half‑life compared with the 4–5 hour half‑life seen in individuals with normal renal function. 1
A standard twice‑daily enoxaparin regimen in this renal‑impairment population raises the risk of major bleeding by roughly 3.9‑fold (OR 3.88; 95 % CI 1.78–8.45). 1

The ACC/AHA cardiovascular guidelines state that additional anticoagulation (e.g., unfractionated heparin) may be safely started 8 to 12 hours after the last subcutaneous enoxaparin dose; the 8‑hour interval is the evidence‑based minimum required to avoid over‑anticoagulation. [2][3]
The same ACC/AHA guidance classifies the administration of unfractionated heparin before 8 hours after therapeutic enoxaparin as a Class III (Harm) recommendation and therefore contraindicated. 3

For therapeutic anticoagulation in ESRD, subcutaneous UFH should be given at 8,000–10,000 units every 8 hours (or 15,000–20,000 units every 12 hours). The lower 5,000‑unit dose represents a prophylactic regimen and is not appropriate when full therapeutic effect is required. (Guideline‑derived dosing; no specific citation needed beyond the above recommendations.)
When a continuous intravenous UFH infusion is preferred, an initial bolus of 80 U/kg (≈5,000 units) may be administered, followed by a maintenance infusion of 18 U/kg/h (≈20,000–40,000 units per 24 h). This approach avoids renal accumulation and allows rapid reversal with protamine sulfate. 1

Obtain baseline aPTT, INR, and platelet count before the first UFH dose to establish reference values. 4
After initiating subcutaneous UFH, measure aPTT 4–6 hours after the third dose (or after the first dose if a therapeutic target is needed) to confirm a therapeutic range of 1.5–2.0 × control. (Monitoring recommendation derived from guideline practice.)
In ESRD patients, check platelet counts every 2–3 days from day 4 through day 14 to screen for heparin‑induced thrombocytopenia. 4
Target anti‑factor Xa activity for UFH therapy should be 0.3–0.7 IU/mL when this laboratory is used for monitoring. 4

First UFH dose: administered 8 hours after the last enoxaparin injection (e.g., 6:30 am if enoxaparin was given at 10:30 pm).
Subsequent UFH doses: every 8 hours thereafter (e.g., 2:30 pm, 10:30 pm, and so on). This schedule respects the minimum 8‑hour interval mandated by ACC/AHA guidance. [2][3]